These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8464593)

  • 1. Activity of cefpodoxime, an oral 3rd generation cephalosporin.
    Raymond N; Lang S
    N Z Med J; 1993 Feb; 106(949):44. PubMed ID: 8464593
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative in vitro antibacterial activities of cefetamet (Ro 15-8074/005), a new oral cephalosporin, and eight other oral antimicrobials.
    Rozgonyi F; Papp-Falusi E; Varga J; Rozgonyi-Szitha K
    J Chemother; 1989 Jul; 1(4 Suppl):119-22. PubMed ID: 16312332
    [No Abstract]   [Full Text] [Related]  

  • 3. In-vitro activity of cefpodoxime proxetil (RU 51807): a comparative disk diffusion study on isolates from geriatric patients.
    Ottomano C; Frugoni S; Berlusconi A; Miseferi G; Mattina R; Anelli M
    J Chemother; 1991 Jan; 3 Suppl 1():62-5. PubMed ID: 12041788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AmpC beta-lactamase-mediated cefpodoxime-resistant Escherichia coli isolated from faecal samples of healthy volunteers.
    Kaneko K; Sato Y; Tokunaga SK; Tamaki SK; Okamoto R; Inoue M
    J Antimicrob Chemother; 2006 Feb; 57(2):369-71. PubMed ID: 16338950
    [No Abstract]   [Full Text] [Related]  

  • 5. Ro 15-8075 (cefetamet pivoxyl), a new oral cephalosporin: in vitro activity of the free acid Ro 15-8074 and regression line analyses.
    Grimm K; Grimm H
    Chemioterapia; 1987 Jun; 6(2 Suppl):84-7. PubMed ID: 3509540
    [No Abstract]   [Full Text] [Related]  

  • 6. Cefpodoxime proxetil--a new oral cephalosporin.
    Med Lett Drugs Ther; 1992 Nov; 34(884):107-8. PubMed ID: 1435506
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cefpodoxime].
    Enferm Infecc Microbiol Clin; 1995; 13(7):437-8. PubMed ID: 8519823
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P; Rand KH; Obermann B; Derendorf H
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections.
    Imaizumi T; Ishikawa H; Hashimoto I
    J Chemother; 1995 Nov; 7 Suppl 4():137-41. PubMed ID: 8904135
    [No Abstract]   [Full Text] [Related]  

  • 10. Microbiological and clinical studies on cefpodoxime proxetil for bacterial skin and soft tissue infections in pediatric patients.
    Ito K; Ito M
    J Chemother; 1995 Nov; 7 Suppl 4():124-6. PubMed ID: 8904131
    [No Abstract]   [Full Text] [Related]  

  • 11. [Reevaluation of current antimicrobials. Cefpodoxime proxetil. Discussion].
    Jpn J Antibiot; 1995 Feb; 48(2):183-90. PubMed ID: 7745807
    [No Abstract]   [Full Text] [Related]  

  • 12. AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity.
    Mori N; Kodama T; Sakai A; Suzuki T; Sugihara T; Yamaguchi S; Nishijima T; Aoki A; Toriya M; Kasai M; Hatano S; Kitagawa M; Yoshimi A; Nishimura K
    Int J Antimicrob Agents; 2001 Nov; 18(5):451-61. PubMed ID: 11711261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of cefpodoxime susceptibility with cephalothin and cefuroxime for urinary tract isolates.
    Bookstaver DA; Bland CM; Woodberry MW; Mansell KB
    J Med Microbiol; 2014 Feb; 63(Pt 2):218-221. PubMed ID: 24214230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility testing of cefpodoxime.
    Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Oct; 28(4):605-7. PubMed ID: 1761456
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid detection of extended-spectrum beta-lactamase (ESBL)-producing organisms in blood culture.
    Weinbren MJ; Borthwick MA
    J Antimicrob Chemother; 2005 Jan; 55(1):131-2. PubMed ID: 15574477
    [No Abstract]   [Full Text] [Related]  

  • 16. Microbiological conclusions.
    Jones RN
    Drugs; 1991; 42 Suppl 3():22-4. PubMed ID: 1726204
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of cefpodoxime, a new oral cephalosporin.
    Stobberingh EE; Houben AW; Philips JH
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):656-8. PubMed ID: 2506031
    [No Abstract]   [Full Text] [Related]  

  • 18. Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil.
    Kakumanu VK; Arora V; Bansal AK
    Int J Pharm; 2006 Jul; 317(2):155-60. PubMed ID: 16621365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretive criteria of antimicrobial disk susceptibility tests with cefpodoxime.
    Grimm H
    Infection; 1991; 19(5):380-2. PubMed ID: 1800381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [(New antimicrobial agent series XLIV): cefpodoxime proxetil].
    Kumazawa J
    Jpn J Antibiot; 1993 Sep; 46(9):749-72. PubMed ID: 8254896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.